Healios K.K (4593) Fundamentals 2026 — Revenue Analysis | SniperIQ
Healios K.K (4593) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥27.3B, trading at ¥254.00 on the JPX. This SniperIQ fundamentals page covers Healios K.K's valuation, profitability (net margin -4235.1%), revenue (¥104M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Healios K.K's market cap?
Healios K.K (4593) has a market capitalization of approximately ¥27.3B, trading at ¥254.00 on the JPX. Market cap moves with the live share price.
What is Healios K.K's P/E ratio?
Healios K.K's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Healios K.K?
Healios K.K runs a net profit margin of -4235.1%, a gross margin of -529.7%, and an operating margin of -5113.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Healios K.K generate?
Healios K.K reported revenue of ¥104M for fiscal year 2025, with net income of -¥2.2B and earnings per share (EPS) of -20.59. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Healios K.K pay a dividend?
Healios K.K does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Healios K.K financially healthy?
Healios K.K carries a debt-to-equity ratio of 0.34x and a current ratio of 2.05x, with a market beta of 1.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Healios K.K a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Healios K.K (4593) the key facts are: market cap ¥27.3B, revenue ¥104M, 52-week range 234-747. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Healios K.K's full fundamentals live
Get Healios K.K's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.